TSX: CMED $12.50 20 Minute Delay -0.20 ( -1.57% ) Volume: 49,056 February 24, 2017

CanniMed Therapeutics Inc.

CanniMed Therapeutics Inc. (CMED) is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry. In addition, CMED has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

CanniMed Ltd., a wholly-owned subsidiary of CMED, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations (MMPR), the predecessor to the current Access to Cannabis for Medical Purposes Regulations (ACMPR).

Prairie Plant Systems Inc., a wholly-owned subsidiary of CMED, was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of diversion.

SubTerra LLC, is a wholly-owned subsidiary of CMED located in White Pine, Michigan, is a key strategic asset in the Company’s longer-term strategy to service a potential medical cannabis market in the United States.

Learn More

Latest News

Featured Presentation